GlassScriptPhysician profile
Andrew D Pham
NPI 1538588868
$45,259.32
in general payments reported to CMS, 2019-2025
71 companies · $5,298 in 2025
The $5,298 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,092 · 2020: $1,266 · 2021: $12K · 2022: $8,908 · 2023: $10K · 2024: $4,733 · 2025: $5,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $6,351 · Long Term Medical Supply Or Device Loan: $499 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,214.05 |
| Food and Beverage | $6,351.01 |
| Long Term Medical Supply Or Device Loan | $498.50 |
| Education | $156.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20,582.25 | 2019-2025 | Enhertu, Calquence, Imjudo |
| Incyte Corporation | $4,842.37 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $3,175.13 | 2019-2025 | Zejula, Jemperli |
| Array Biopharma INC | $1,479.02 | 2019-2025 | Braftovi, Tukysa, Mektovi |
| Bayer Healthcare Pharmaceuticals INC. | $1,361.08 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $1,212.51 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $1,145.33 | 2020-2025 | |
| Amgen INC. | $942.95 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Janssen Biotech, INC. | $554.70 | 2020-2025 | Tecvayli, Darzalex, Talvey |
| Genentech USA, INC. | $533.16 | 2019-2025 | Polivy |
| E.R. Squibb & Sons, L.L.C. | $509.07 | 2019-2025 | Opdivo |
| Seagen INC. | $485.52 | 2019-2022 | |
| Genzyme Corporation | $472.29 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $460.96 | 2019-2022 | |
| Gilead Sciences, INC. | $432.18 | 2019-2025 | Trodelvy |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $425.73 | 2020-2025 | |
| Puma Biotechnology, INC. | $366.73 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $358.50 | 2022-2025 | Fruzaqla, Iclusig, Ninlaro |
| Alexion Pharmaceuticals, INC. | $352.78 | 2019-2025 | Ultomiris |
| Daiichi Sankyo INC. | $349.00 | 2020-2025 | Enhertu, Vanflyta, Datroway |
| Lilly USA, LLC | $306.74 | 2021-2025 | Jaypirca, Verzenio |
| Apellis Pharmaceuticals, INC. | $283.44 | 2022-2025 | Empaveli |
| Abbvie INC. | $246.49 | 2020-2025 | |
| Astellas Pharma US INC | $233.41 | 2021-2024 | |
| Exelixis INC. | $223.21 | 2020-2024 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $215.32 | 2019-2025 | Onivyde, Somatuline Depot |
| Novocure INC. | $201.22 | 2021-2024 | Optune Lua (Novottf-200t) |
| Jazz Pharmaceuticals INC. | $197.40 | 2024-2025 | |
| Kite Pharma, INC. | $192.92 | 2019-2025 | Yescarta |
| Myriad Genetic Laboratories, INC. | $188.11 | 2022-2024 | Myrisk |
| Karyopharm Therapeutics INC. | $175.19 | 2020-2025 | Xpovio |
| Tempus Ai, INC | $174.96 | 2024-2025 | Xt Cdx |
| Foundation Medicine, INC. | $172.04 | 2020-2023 | Foundationone Liquid Cdx |
| Coherus Oncology, INC. | $168.39 | 2021-2025 | Loqtorzi |
| Acrotech Biopharma INC. | $167.95 | 2021-2023 | Beleodaq |
| Aveo Pharmaceuticals, INC. | $164.50 | 2022-2025 | |
| Eisai INC. | $162.48 | 2021-2025 | |
| Celgene Corporation | $143.33 | 2020-2025 | Reblozyl |
| Blueprint Medicines Corporation | $129.96 | 2020-2025 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $119.70 | 2025 | Dawnzera |
| Adc Therapeutics America, INC. | $112.22 | 2022-2025 | |
| Emd Serono, INC. | $88.80 | 2021-2024 | |
| Beone Medicines USA, INC. | $87.73 | 2025 | Brukinsa |
| Springworks Therapeutics, INC. | $80.94 | 2024-2025 | Ogsiveo |
| Taiho Oncology, INC. | $75.50 | 2021-2024 | |
| Stemline Therapeutics INC. | $70.97 | 2025 | Orserdu |
| Genmab U.S., INC. | $68.92 | 2024-2025 | Epkinly |
| Deciphera Pharmaceuticals INC. | $68.29 | 2024-2025 | Qinlock, Romvimza |
| Myovant Sciences INC. | $67.10 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $66.64 | 2019 | |
| Beigene USA, INC. | $61.84 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.71 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $46.70 | 2019-2020 | |
| G1 Therapeutics, INC. | $40.00 | 2022 | |
| Morphosys, US INC. | $39.16 | 2021-2022 | |
| Boston Scientific Corporation | $38.60 | 2025 | General - Embolics |
| Bioventus LLC | $28.81 | 2022 | |
| Geron Corporation | $26.96 | 2025 | Rytelo |
| Csl Behring | $25.30 | 2025 | Privigen, Kcentra |
| Tolmar Pharmaceuticals, INC. | $24.52 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.05 | 2021 | |
| Global Blood Therapeutics, INC. | $19.75 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.75 | 2022 | |
| Tg Therapeutics, INC. | $19.75 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.67 | 2019 | |
| Pharmacosmos Therapeutics INC. | $18.66 | 2025 | Monoferric |
| Dova Pharmaceuticals | $18.25 | 2021 | |
| Clovis Oncology, INC. | $14.91 | 2020 | |
| Advanced Accelerator Applications | $12.66 | 2020 | |
| Janssen Scientific Affairs, LLC | $7.14 | 2024 | Imbruvica, Darzalex, Carvykti |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.